Pelthos Appoints John M. Gay as CFO Effective April 10
Pelthos Therapeutics appointed SVP of Finance & Accounting John M. Gay as CFO effective April 10, 2026, replacing Francis Knuettel II after his nine-month tenure. Gay has over 25 years of public company finance experience, including CFO roles at LNHC and senior finance positions at Furiex Pharmaceuticals.
1. CFO Transition at Pelthos
Pelthos named SVP of Finance & Accounting John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who served since July 2025.
2. John M. Gay’s Career Background
Gay has over 25 years of experience in public company finance and accounting, including a prior CFO role at LNHC, Inc., senior finance positions at Furiex Pharmaceuticals, and early career work at Deloitte and Arthur Andersen.
3. Strategic Context and Growth Plans
The CFO transition follows Pelthos’s two recent significant capital raises and supports its commercial-stage focus on products such as ZELSUVMI, Xepi and Xeglyze as it advances its cutaneous infectious disease portfolio.